Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke

• Published in: Stroke (1970) 1997-03, Vol.28 (3), p.580-583
• Main Authors: DYKER, A. G, GROSSET, D. G, LEES, K
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive agents; Biological and medical sciences; Blood Pressure - drug effects; Brain Ischemia - diagnostic imaging; Brain Ischemia - drug therapy; Brain Ischemia - physiopathology; Cardiovascular system; Cerebrovascular Circulation - drug effects; Cerebrovascular Disorders - diagnostic imaging; Cerebrovascular Disorders - drug therapy; Cerebrovascular Disorders - physiopathology; Double-Blind Method; Female; Humans; Hypertension - diagnostic imaging; Hypertension - drug therapy; Indoles - therapeutic use; Male; Medical sciences; Middle Aged; Perindopril; Pharmacology. Drug treatments; Placebos; Ultrasonography
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/01.STR.28.3.580

The relationship between high blood pressure and the incidence of stroke is well established. Currently the effects of lowering blood pressure in patients with established cerebrovascular disease is undetermined, and there is continuing concern regarding the treatment of patients soon after a stroke event. Angiotensin-converting enzyme inhibitors maintain cerebral blood flow despite lowering blood pressure in patients with heart failure and otherwise uncomplicated hypertension. We tested the hypothesis that perindopril, an angiotensin-converting enzyme inhibitor with a gradual onset of action and a minimal first-dose hypotensive effect, lowers blood pressure without adversely affecting cerebral blood flow in patients 2 to 7 days after symptoms of cerebral infarction. Patients were randomized to receive 15 days of oral perindopril (4 mg) or placebo in a double-blind study. Blood pressure was monitored semiautomatically. Cerebral blood flow was calculated from internal carotid artery and vertebral Doppler ultrasound, supplemented by middle cerebral artery blood velocities. Twenty-four patients completed the protocol; four additional patients were withdrawn for reasons unrelated to treatment. Patients on perindopril had a placebo-corrected reduction in blood pressure of 19/11 mm Hg. Blood pressure remained reduced after 2 weeks of treatment. In contrast, total cerebral blood flow was unaffected by perindopril. Neurological symptoms improved similarly in both groups. Perindopril was well tolerated and effectively reduced blood pressure without reducing carotid territory blood flow in patients with symptoms of recent cerebral ischemia.